Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications; and TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; and TransCon Ranibizumab, a compound to support injection of ranibizumab. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.